Inovio Pharmaceuticals, Inc. (INO)
After hours:
| Previous close | 2.3600 |
| Open | 2.2400 |
| Bid | 2.0800 x 38800 |
| Ask | 2.0900 x 34100 |
| Day's range | 2.0200 - 2.2500 |
| 52-week range | 1.3800 - 9.9600 |
| Volume | |
| Avg. volume | 7,121,593 |
| Market cap | 480.986M |
| Beta (5Y monthly) | 0.88 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.5420 |
| Earnings date | 09 Aug 2022 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 5.60 |
- PR Newswire
INOVIO Reports Financial Results and Highlights for the Second Quarter 2022
INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help protect people from infectious diseases and treat people with cancer and HPV-associated diseases, today reported financial results for the quarter and six months ended June 30, 2022. INOVIO's management will host a live conference call and webcast at 4:30 p.m. Eastern Daylight Time (EDT) today to discuss financial results and provide a general business update for the second quarter. The
- Zacks
Inovio Pharmaceuticals (INO) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Inovio (INO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Simply Wall St.
Shareholders in Inovio Pharmaceuticals (NASDAQ:INO) are in the red if they invested a year ago
It's not a secret that every investor will make bad investments, from time to time. But it's not unreasonable to try to...
